Cadherins Glycans in Cancer: Sweet Players in a Bitter Process

Trends in Cancer

Volumn 2, Issue 9, 2016, Pages 519-531

  Carvalho, Sandra ^a,b   Reis, Celso A ^a,b,c   Pinho, Salomé S ^a,b,c  

^a UNIVERSITY OF PORTO   (Portugal)

^b UNIVERSITY OF PORTO   (Portugal)

^c University of Porto   (Portugal)

Author keywords

cancer progression; classical cadherin; glycosylation; invasion; metastasis; N glycosylation; O glycosylation

Indexed keywords

CADHERIN; GLYCAN; TUMOR MARKER; POLYSACCHARIDE;

CANCER CELL; CANCER GROWTH; CANCER INHIBITION; CELL ADHESION; HUMAN; METASTASIS; PRIORITY JOURNAL; PROTEIN GLYCOSYLATION; REVIEW; TUMOR INVASION; ANIMAL; GLYCOSYLATION; METABOLISM; NEOPLASM; PATHOLOGY;

ANIMALS; BIOMARKERS, TUMOR; CADHERINS; CELL ADHESION; GLYCOSYLATION; HUMANS; NEOPLASMS; POLYSACCHARIDES;

EID: 84989821862     PISSN: 24058033     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.trecan.2016.08.003     Document Type: Review

References (149)

1. 1 Jiang, W.G., et al. Tissue invasion and metastasis: molecular, biological and clinical perspectives. Semin Cancer Biol. 35:Suppl. (2015), S244–S275.
2. 2 Pinho, S.S., Reis, C.A., Glycosylation in cancer: mechanisms and clinical implications. Nat. Rev. Cancer 15 (2015), 540–555.
3. 3 Vestweber, D., Cadherins in tissue architecture and disease. J. Mol. Med. 93 (2015), 5–11.
4. 4 Niessen, C.M., et al. Tissue organization by cadherin adhesion molecules: dynamic molecular and cellular mechanisms of morphogenetic regulation. Physiol. Rev. 91 (2011), 691–731.
5. 5 Padmanabhan, A., et al. Jack of all trades: functional modularity in the adherens junction. Curr. Opin. Cell Biol. 36 (2015), 32–40.
6. 6 Hoffman, B.D., Yap, A.S., Towards a dynamic understanding of cadherin-based mechanobiology. Trends Cell Biol. 25 (2015), 803–814.
7. 7 Leckband, D.E., de Rooij, J., Cadherin adhesion and mechanotransduction. Annu. Rev. Cell Dev. Biol. 30 (2014), 291–315.
8. 8 Gheldof, A., Berx, G., Cadherins and epithelial-to-mesenchymal transition. Prog. Mol. Biol. Transl. Sci. 116 (2013), 317–336.
9. 9 van Roy, F., Beyond E-cadherin: roles of other cadherin superfamily members in cancer. Nat. Rev. Cancer 14 (2014), 121–134.
10. 10 Berx, G., van Roy, F., Involvement of members of the cadherin superfamily in cancer. Cold Spring Harb. Perspect. Biol., 1, 2009, a003129.
11. 11 van Roy, F., Berx, G., The cell–cell adhesion molecule E-cadherin. Cell Mol. Life Sci. 65 (2008), 3756–3788.
12. 12 Sang-Hyuk Lee, S.H., et al. Loss of heterozygosity of tumor suppressor genes (p16, Rb, E-cadherin, p53) in hypopharynx squamous cell carcinoma. Otolaryngol. Head Neck Surg. 145 (2011), 64–70.
13. 13 Palacios, J., et al. Frequent E-cadherin gene inactivation by loss of heterozygosity in pleomorphic lobular carcinoma of the breast. Mod. Pathol. 16 (2003), 674–678.
14. 14 van der Post, R.S., et al. Hereditary diffuse gastric cancer: updated clinical guidelines with an emphasis on germline CDH1 mutation carriers. J. Med. Genet. 52 (2015), 361–374.
15. 15 Corso, G., et al. E-Cadherin germline mutation carriers: clinical management and genetic implications. Cancer Metastasis Rev. 33 (2014), 1081–1094.
16. 16 Shargh, S.A., et al. Downregulation of E-cadherin expression in breast cancer by promoter hypermethylation and its relation with progression and prognosis of tumor. Med. Oncol., 31, 2014, 250.
17. 17 Caldeira, J.R., et al. CDH1 promoter hypermethylation and E-cadherin protein expression in infiltrating breast cancer. BMC Cancer, 6, 2006, 48.
18. 18 Mazda, M., et al. E-Cadherin is transcriptionally activated via suppression of ZEB1 transcriptional repressor by small RNA-mediated gene silencing. PLoS ONE, 6, 2011, e28688.
19. 19 Hirata, E., et al. Retrograde flow of cadherins in collective cell migration. Nat. Cell Biol. 16 (2014), 621–623.
20. 20 Mellman, I., Yarden, Y., Endocytosis and cancer. Cold Spring Harb. Perspect. Biol., 5, 2013, a016949.
21. 21 Hu, Q.P., et al. Beyond a tumor suppressor: soluble E-cadherin promotes the progression of cancer. Int. J. Cancer 138 (2016), 2804–2812.
22. 22 Corso, G., et al. Somatic mutations and deletions of the E-cadherin gene predict poor survival of patients with gastric cancer. J. Clin. Oncol. 31 (2013), 868–875.
23. 23 Pinho, S.S., et al. Gastric cancer: adding glycosylation to the equation. Trends Mol. Med. 19 (2013), 664–676.
24. 24 Zhao, Y., et al. Branched N-glycans regulate the biological functions of integrins and cadherins. FEBS J. 275 (2008), 1939–1948.
25. 25 Moremen, K.W., et al. Vertebrate protein glycosylation: diversity, synthesis and function. Nat. Rev. Mol. Cell Biol. 13 (2012), 448–462.
26. 26 Bard, F., Chia, J., Cracking the glycome encoder: signaling, trafficking, and glycosylation. Trends Cell Biol. 26 (2016), 379–388.
27. 27 Hart, G.W., Thematic minireview series on glycobiology and extracellular matrices: glycan functions pervade biology at all levels. J. Biol. Chem., 288, 2013 6903-6903.
28. 28 Munkley, J., Elliott, D.J., Hallmarks of glycosylation in cancer. Oncotarget, 2016, 10.18632/oncotarget.8155 Published online March 17, 2016.
29. 29 Stowell, S.R., et al. Protein glycosylation in cancer. Annu. Rev. Pathol. 10 (2015), 473–510.
30. 30 Reis, C.A., et al. Alterations in glycosylation as biomarkers for cancer detection. J. Clin. Pathol. 63 (2010), 322–329.
31. 31 Cherepanova, N., et al. N-Linked glycosylation and homeostasis of the endoplasmic reticulum. Curr. Opin. Cell Biol. 41 (2016), 57–65.
32. 32 Shental-Bechor, D., Levy, Y., Effect of glycosylation on protein folding: a close look at thermodynamic stabilization. Proc. Natl. Acad. Sci. U.S.A. 105 (2008), 8256–8261.
33. 33 Xu, C., Ng, D.T.W., Glycosylation-directed quality control of protein folding. Nat. Rev. Mol. Cell Biol. 16 (2015), 742–752.
34. 34 Lee, H.S., et al. Effects of N-glycosylation on protein conformation and dynamics: Protein Data Bank analysis and molecular dynamics simulation study. Sci. Rep., 5, 2015, 8926.
35. 35 Zhu, W., et al. Cytoplasmic O-glycosylation prevents cell surface transport of E-cadherin during apoptosis. EMBO J. 20 (2001), 5999–6007.
36. 36 Geng, F., et al. Multiple post-translational modifications regulate E-cadherin transport during apoptosis. J. Cell Sci. 125 (2012), 2615–2625.
37. 37 Hall, M.K., et al. Glycan structures contain information for the spatial arrangement of glycoproteins in the plasma membrane. PLoS ONE, 8, 2013, e75013.
38. 38 Hall, M.K., et al. Cell surface N-glycans influence the level of functional E-cadherin at the cell–cell border. FEBS Open Bio. 4 (2014), 892–897.
39. 39 Hall, M.K., et al. Predominant expression of hybrid N-glycans has distinct cellular roles relative to complex and oligomannose N-glycans. Int. J. Mol. Sci., 17, 2016, 925.
40. 40 Shashikanth, N., et al. Kinetic leasurements reveal enhanced protein-protein interactions at intercellular junctions. Sci. Rep., 6, 2016, 23623.
41. 41 Langer, M.D., et al. N-Glycosylation alters cadherin-mediated intercellular binding kinetics. J. Cell Sci. 125 (2012), 2478–2485.
42. 42 Guo, H-B., et al. Regulation of homotypic cell–cell adhesion by branched N-glycosylation of N-cadherin extracellular EC2 and EC3 domains. J. Biol. Chem. 284 (2009), 34986–34997.
43. 43 Vester-Christensen, M.B., et al. Mining the O-mannose glycoproteome reveals cadherins as major O-mannosylated glycoproteins. Proc. Natl. Acad. Sci. U.S.A. 110 (2013), 21018–21023.
44. 44 Baenziger, J.U., O-Mannosylation of cadherins. Proc. Natl. Acad. Sci. U.S.A. 110 (2013), 20858–20859.
45. 45 Lommel, M., et al. Protein O-mannosylation is crucial for E-cadherin–mediated cell adhesion. Proc. Natl. Acad. Sci. U.S.A. 110 (2013), 21024–21029.
46. 46 Winterhalter, P.R., et al. O-Glycosylation of the non-canonical T-cadherin from rabbit skeletal muscle by single mannose residues. FEBS Lett. 587 (2013), 3715–3721.
47. 47 Pinho, S.S., et al. Modulation of E-cadherin function and dysfunction by N-glycosylation. Cell. Mol. Life. Sci. 68 (2011), 1011–1020.
48. 48 Liwosz, A., et al. N-Glycosylation affects the molecular organization and stability of E-cadherin junctions. J. Biol. Chem. 281 (2006), 23138–23149.
49. 49 Jamal, B.T., et al. N-Glycosylation status of E-cadherin controls cytoskeletal dynamics through the organization of distinct β-catenin- and γ-catenin-containing AJs. Cell Health Cytoskelet. 2009 (2009), 67–80.
50. 50 Nita-Lazar, M., et al. Hypoglycosylated E-cadherin promotes the assembly of tight junctions through the recruitment of PP2A to adherens junctions. Exp. Cell Res. 316 (2010), 1871–1884.
51. 51 Taniguchi, N., Kizuka, Y., Glycans and cancer: role of N-Glycans in cancer biomarker, progression and metastasis, and therapeutics. Richard, R.D., Lauren, E.B., (eds.) Advances in Cancer Research, 2015, Academic Press, 11–51.
52. 52 Zhao, Y-P., et al. Decreased core-fucosylation contributes to malignancy in gastric cancer. PLoS ONE, 9, 2014, e94536.
53. 53 Liu, L., et al. The identification and characterization of novel N-glycan-based biomarkers in gastric cancer. PLoS ONE, 8, 2013, e77821.
54. 54 Osumi, D., et al. Core fucosylation of E-cadherin enhances cell–cell adhesion in human colon carcinoma WiDr cells. Cancer Sci. 100 (2009), 888–895.
55. 55 Hu, P., et al. E-Cadherin core fucosylation regulates nuclear β-catenin accumulation in lung cancer cells. Glycoconj. J. 25 (2008), 843–850.
56. 56 Shao, K., et al. Posttranslational modification of E-cadherin by core fucosylation regulates Src activation and induces epithelial–mesenchymal transition-like process in lung cancer cells. Glycobiology 26 (2016), 142–154.
57. 57 Wen, C-L., et al. Development of an AlphaLISA assay to quantify serum core-fucosylated E-cadherin as a metastatic lung adenocarcinoma biomarker. J. Proteomics 75 (2012), 3963–3976.
58. 58 Kizuka, Y., Taniguchi, N., Enzymes for N-glycan branching and their genetic and nongenetic regulation in cancer. Biomolecules, 6, 2016, 25.
59. 59 Buckhaults, P., et al. Transcriptional regulation of N-acetylglucosaminyltransferase V by the src oncogene. J. Biol. Chem. 272 (1997), 19575–19581.
60. 60 Huang, B., et al. Expression of N-acetylglucosaminyltransferase V in gastric cancer correlates with metastasis and prognosis. Int. J. Oncol. 44 (2014), 849–857.
61. 61 Murata, K., et al. Expression of N-acetylglucosaminyltransferase V in colorectal cancer correlates with metastasis and poor prognosis. Am. Assoc. Cancer Res. 6 (2000), 1772–1777.
62. + T cells and macrophages. J. Immunol. 180 (2008), 3158–3165.
63. 63 Demetriou, M., et al. Reduced contact-inhibition and substratum adhesion in epithelial cells expressing GlcNAc-transferase V. J. Cell Biol. 130 (1995), 383–392.
64. 64 Guo, H-B., et al. Specific posttranslational modification regulates early events in mammary carcinoma formation. Proc. Natl. Acad. Sci. U.S.A. 107 (2010), 21116–21121.
65. min/+ mice through altered Wnt receptor signaling. J. Biol. Chem. 289 (2014), 31534–31549.
66. 66 Wei, T., et al. Down-regulation of GnT-V inhibits nasopharyngeal carcinoma cell CNE-2 malignancy in vitro and in vivo. Cancer Lett. 309 (2011), 151–161.
67. 67 Granovsky, M., et al. Suppression of tumor growth and metastasis in Mgat5-deficient mice. Nat. Med. 6 (2000), 306–312.
68. 68 Elola, M.T., et al. Assembly, organization and regulation of cell-surface receptors by lectin–glycan complexes. Biochem. J. 469 (2015), 1–16.
69. 69 Nabi, I.R., et al. The galectin lattice at a glance. J. Cell Sci. 128 (2015), 2213–2219.
70. 70 Pinho, S.S., et al. The role of N-acetylglucosaminyltransferase III and V in the post-transcriptional modifications of E-cadherin. Hum. Mol. Genet. 18 (2009), 2599–2608.
71. 71 Pinho, S.S., et al. E-Cadherin and adherens-junctions stability in gastric carcinoma: Functional implications of glycosyltransferases involving N-glycan branching biosynthesis, N-acetylglucosaminyltransferases III and V. Biochim. Biophys. Acta (BBA) - Gen. Sub. 1830 (2013), 2690–2700.
72. 72 Carvalho, S., et al. Preventing E-cadherin aberrant N-glycosylation at Asn-554 improves its critical function in gastric cancer. Oncogene 35 (2016), 1619–1631.
73. 73 Pinho, S.S. and Reis, C.A. (2011) E-cadherin glycosylation in cancer. In Glycoscience: Biology and Medicine (Endo, T. et al. eds), pp. 1-6, Springer Japan.
74. 74 Guo, H-B., et al. N-Acetylglucosaminyltransferase V expression levels regulate cadherin-associated homotypic cell–cell adhesion and intracellular signaling pathways. J. Biol. Chem. 278 (2003), 52412–52424.
75. 75 Zhao, H., et al. N-Glycosylation at Asn residues 554 and 566 of E-cadherin affects cell cycle progression through extracellular signal-regulated protein kinase signaling pathway. Acta Biochim. Biophys. Sin. (Shanghai). 40 (2008), 140–148.
76. 76 Zhao, H., et al. N-Glycosylation affects the adhesive function of E-Cadherin through modifying the composition of adherens junctions (AJs) in human breast carcinoma cell line MDA-MB-435. J. Cell. Biochem. 104 (2008), 162–175.
77. 77 Varelas, X., et al. Protein N-glycosylation in oral cancer: dysregulated cellular networks among DPAGT1, E-cadherin adhesion and canonical Wnt signaling. Glycobiology 24 (2014), 579–591.
78. 78 Nita-Lazar, M., et al. Overexpression of DPAGT1 leads to aberrant N-glycosylation of E-cadherin and cellular discohesion in oral cancer. Cancer Res. 69 (2009), 5673–5680.
79. 79 Zhou, F., et al. Unglycosylation at Asn-633 made extracellular domain of E-cadherin folded incorrectly and arrested in endoplasmic reticulum, then sequentially degraded by ERAD. Glycoconj. J. 25 (2008), 727–740.
80. 80 Büll, C., et al. Sialic acids sweeten a tumor's life. Cancer Res. 74 (2014), 3199–3204.
81. 81 Dall'Olio, F., et al. Sialosignaling: sialyltransferases as engines of self-fueling loops in cancer progression. Biochim. Biophys. Acta Gen. Sub. 1840 (2014), 2752–2764.
82. 82 Varki, A., Essentials of Glycobiology. 2009, Cold Spring Harbor Laboratory Press.
83. 83 Langereis, M.A., et al. Complexity and diversity of the mammalian sialome revealed by nidovirus virolectins. Cell Rep. 11 (2015), 1966–1978.
84. 84 Pinho, S.S., et al. Molecular plasticity of E-cadherin and sialyl Lewis X expression, in two comparative models of mammary tumorigenesis. PLoS ONE, 4, 2009, e6636.
85. 85 Lin, S., et al. Cell surface α2,6-sialylation affects adhesion of breast carcinoma cells. Exp. Cell Res. 276 (2002), 101–110.
86. 86 Schultz, M.J., et al. The tumor-associated glycosyltransferase ST6Gal-I regulates stem cell transcription factors and confers a cancer stem cell phenotype. Cancer Res. 76 (2016), 3978–3988.
87. 87 Carvalho, S., et al. O-Mannosylation and N-glycosylation: two coordinated mechanisms regulating the tumour suppressor functions of E-cadherin in cancer. Oncotarget., 2016, 10.18632/oncotarget.11245 Published online August 12, 2016.
88. 88 Jin, F-Z., et al. A correlation between altered O-GlcNAcylation, migration and with changes in E-cadherin levels in ovarian cancer cells. Exp. Cell Res. 319 (2013), 1482–1490.
89. 89 Chaiyawat, P., et al. Aberrant O-GlcNAcylated proteins: new perspectives in breast and colorectal cancer. Front. Endocrinol. (Lausanne)., 5, 2014, 193.
90. 90 Saldova, R., et al. Core fucosylation and α2-3 sialylation in serum N-glycome is significantly increased in prostate cancer comparing to benign prostate hyperplasia. Glycobiology 21 (2011), 195–205.
91. 91 Zhao, Y., et al. Modification of sialylation mediates the invasive properties and chemosensitivity of human hepatocellular carcinoma. Mol. Cell. Proteomics 13 (2014), 520–536.
92. 92 Park, J-J., Lee, M., Increasing the α2,6 sialylation of glycoproteins may contribute to metastatic spread and therapeutic resistance in colorectal cancer. Gut. Liver 7 (2013), 629–641.
93. 93 Schultz, M.J., et al. Regulation of the metastatic cell phenotype by sialylated glycans. Cancer Metastasis Rev. 31 (2012), 501–518.
94. 94 Alpaugh, M.L., et al. Cooperative role of E-cadherin and sialyl-Lewis X/A-deficient MUC1 in the passive dissemination of tumor emboli in inflammatory breast carcinoma. Oncogene 21 (2002), 3631–3643.
95. 95 Gomes, C., et al. Expression of ST3GAL4 leads to SLe(x) expression and induces c-Met Activation and an invasive phenotype in gastric carcinoma cells. PLoS ONE, 8, 2013, e66737.
96. 96 Bassagañas, S., et al. Pancreatic cancer cell glycosylation regulates cell adhesion and invasion through the modulation of α2β1 integrin and E-cadherin function. PLoS ONE, 9, 2014, e98595.
97. 97 Siddiqui, S.F., et al. Coexpression of β1,6-N-acetylglucosaminyltransferase V glycoprotein substrates defines aggressive breast cancers with poor outcome. Cancer Epidemiol. Biomarkers Prev. 14 (2005), 2517–2523.
98. 98 Huang, B., et al. Downregulation of the GnT-V gene inhibits metastasis and invasion of BGC823 gastric cancer cells. Oncol. Rep. 29 (2013), 2392–2400.
99. 99 Lee, J.H., et al. N-Acetylglucosaminyltransferase V triggers overexpression of MT1-MMP and reinforces the invasive/metastatic potential of cancer cells. Biochem. Biophys. Res. Commun. 431 (2013), 658–663.
100. 100 Kim, Y-S., et al. Functional proteomics study reveals that N-acetylglucosaminyltransferase V reinforces the invasive/metastatic potential of colon cancer through aberrant glycosylation on tissue inhibitor of metalloproteinase. Mol. Cell. Proteomics 7 (2008), 1–14.
101. 101 Terao, M., et al. Enhanced epithelial–mesenchymal transition-like phenotype in N-acetylglucosaminyltransferase V transgenic mouse skin promotes wound healing. J. Biol. Chem. 286 (2011), 28303–28311.
102. 102 Ihara, Y., et al. cDNA cloning, expression, and chromosomal localization of human N-acetylglucosaminyltransferase III (GnT-III). J. Biochem. 113 (1993), 692–698.
103. 103 Nagae, M., et al. Atomic visualization of a flipped-back conformation of bisected glycans bound to specific lectins. Sci. Rep., 6, 2016, 22973.
104. 104 Re, S., et al. Structural diversity and changes in conformational equilibria of biantennary complex-type N-glycans in water revealed by replica-exchange molecular dynamics simulation. Biophys. J. 101 (2011), L44–L46.
105. 105 Taniguchi, N., et al. Implication of N-acetylglucosaminyltransferases III and V in cancer: gene regulation and signaling mechanism. Biochim. Biophys. Acta Mol. Basis Dis. 1455 (1999), 287–300.
106. 106 Zhao, Y., et al. N-Acetylglucosaminyltransferase III antagonizes the effect of N-acetylglucosaminyltransferase V on α3β1 integrin-mediated cell migration. J. Biol. Chem. 281 (2006), 32122–32130.
107. 107 Song, Y., et al. The bisecting GlcNAc on N-glycans inhibits growth factor signaling and retards mammary tumor progression. Cancer Res. 70 (2010), 3361–3371.
108. 108 Yoshimura, M., et al. Suppression of lung metastasis of B16 mouse melanoma by N-acetylglucosaminyltransferase III gene transfection. Proc. Natl. Acad. Sci. U.S.A. 92 (1995), 8754–8758.
109. 109 Kitada, T., et al. The addition of bisecting N-acetylglucosamine residues to e-cadherin down-regulates the tyrosine phosphorylation of β-catenin. J. Biol. Chem. 276 (2001), 475–480.
110. 110 Yoshimura, M., et al. Aberrant glycosylation of E-cadherin enhances cell–cell binding to suppress metastasis. J. Biol. Chem. 271 (1996), 13811–13815.
111. 111 Akama, R., et al. N-Acetylglucosaminyltransferase III expression is regulated by cell–cell adhesion via the E-cadherin–catenin–actin complex. Proteomics 8 (2008), 3221–3228.
112. 112 Iijima, J., et al. Cell–cell interaction-dependent regulation of N-acetylglucosaminyltransferase III and the bisected N-glycans in GE11 epithelial cells: involvement of e-cadherin-mediated cell adhesion. J. Biol. Chem. 281 (2006), 13038–13046.
113. 113 Xu, Q., et al. Wnt/β-catenin signaling down-regulates N-acetylglucosaminyltransferase III Expression: the implications of two mutually exclusive pathways for regulation. J. Biol. Chem. 286 (2011), 4310–4318.
114. 114 Xu, Q., et al. Roles of N-acetylglucosaminyltransferase III in epithelial-to-Mesenchymal transition induced by transforming growth factor β1 (TGF-β1) in epithelial cell lines. J. Biol. Chem. 287 (2012), 16563–16574.
115. 115 Pinho, S.S., et al. Loss and recovery of Mgat3 and GnT-III mediated E-cadherin N-glycosylation is a mechanism involved in epithelial–mesenchymal–Epithelial Transitions. PLoS ONE, 7, 2012, e33191.
116. 116 de Gramont, A., et al. Pragmatic issues in biomarker evaluation for targeted therapies in cancer. Nat. Rev. Clin. Oncol. 12 (2015), 197–212.
117. 117 Oliveira, C. et al. Familial gastric cancer: genetic susceptibility, pathology, and implications for management. Lancet Oncol. 16, e60-70.
118. 118 Christgen, M., et al. Lobular breast cancer: clinical, molecular and morphological characteristics. Pathol. Res. Pract. 212 (2016), 583–597.
119. 119 Weiß, J.V., et al. Soluble E-cadherin as a serum biomarker candidate: Elevated levels in patients with late-stage colorectal carcinoma and FAP. Int. J. Cancer 128 (2011), 1384–1392.
120. 120 Mestre, T., et al. Quantification of topological features in cell meshes to explore E-cadherin dysfunction. Sci. Rep., 6, 2016, 25101.
121. 121 Kuefer, R., et al. The role of an 80 kDa fragment of E-cadherin in the metastatic progression of prostate cancer. Am. Assoc. Cancer Res. 9 (2003), 6447–6452.
122. 122 Chan, A., et al. Soluble E-cadherin is a valid prognostic marker in gastric carcinoma. Gut 48 (2001), 808–811.
123. 123 Almeida, A., Kolarich, D., The promise of protein glycosylation for personalised medicine. Biochim. Biophys. Acta Gen. Sub. 1860 (2016), 1583–1595.
124. 124 Mehta, N., et al. Mass spectrometric quantification of N-linked glycans by reference to exogenous standards. J. Proteome Res., 2016, 10.1021/acs.jproteome.6b00132 Published online July 19, 2016.
125. 125 Fuster, M.M., Esko, J.D., The sweet and sour of cancer: glycans as novel therapeutic targets. Nat. Rev. Cancer 5 (2005), 526–542.
126. 126 Kolarich, D., et al. Determination of site-specific glycan heterogeneity on glycoproteins. Nat. Protocols 7 (2012), 1285–1298.
127. 127 Patwa, T., et al. Glycoprotein analysis using protein microarrays and mass spectrometry. Mass Spectrom. Rev. 29 (2010), 830–844.
128. 128 Mereiter, S., et al. Glycomic and sialoproteomic data of gastric carcinoma cells overexpressing ST3GAL4. Data Brief 7 (2016), 814–833.
129. 129 Campos, D., et al. Probing the O-glycoproteome of gastric cancer cell lines for biomarker discovery. Mol. Cell. Proteomics 14 (2015), 1616–1629.
130. 130 Muthana, S.M., Gildersleeve, J.C., Factors affecting anti-glycan IgG and IgM repertoires in human serum. Sci. Rep., 6, 2016, 19509.
131. 131 Pochechueva, T., et al. Comparison of printed glycan array, suspension array and ELISA in the detection of human anti-glycan antibodies. Glycoconj. J. 28 (2011), 507–517.
132. 132 Peng, W., et al. Glycan microarray screening assay for glycosyltransferase specificities. Brockhausen, I., (eds.) Glycosyltransferases: Methods and Protocols, 2013, Humana Press, 1–14.
133. 133 Rillahan, C.D., Paulson, J.C., Glycan microarrays for decoding the glycome. Annu. Rev. Biochem. 80 (2011), 797–823.
134. 134 Narimatsu, H., et al. A strategy for discovery of cancer glyco-biomarkers in serum using newly developed technologies for glycoproteomics. FEBS J. 277 (2010), 95–105.
135. 135 Ghirardello, M., et al. Glycomimetics targeting glycosyltransferases: synthetic, computational and structural studies of less-polar conjugates. Chemistry 22 (2016), 7215–7224.
136. 136 Wu, Y., et al. Cooperativity between trans and cis interactions in cadherin-mediated junction formation. Proc. Natl. Acad. Sci. U.S.A. 107 (2010), 17592–17597.
137. 137 Zhang, Y., et al. Resolving cadherin interactions and binding cooperativity at the single-molecule level. Proc. Natl. Acad. Sci. U.S.A. 106 (2009), 109–114.
138. 138 Ishiyama, N., Ikura, M., The three-dimensional structure of the cadherin–catenin complex. Harris, T., (eds.) Adherens Junctions: from Molecular Mechanisms to Tissue Development and Disease, 2012, Springer, Netherlands, 39–62.
139. 139 Nanes, B.A., Kowalczyk, A.P., Adherens junction turnover: regulating adhesion through cadherin endocytosis, degradation, and recycling. Subcel. Biochem. 60 (2012), 197–222.
140. 140 Baum, B., Georgiou, M., Dynamics of adherens junctions in epithelial establishment, maintenance, and remodeling. J. Cell Biol. 192 (2011), 907–917.
141. 141 Cummings, R.D., Pierce, J.M., The challenge and promise of glycomics. Chem. Biol. 21 (2014), 1–15.
142. 142 Stanley, P., Golgi glycosylation. Cold Spring Harb. Perspect. Biol., 3, 2011, a005199.
143. 143 Jensen, P.H., et al. Mucin-type O-glycosylation – putting the pieces together. FEBS J. 277 (2010), 81–94.
144. 144 Neubert, P., Strahl, S., Protein O-mannosylation in the early secretory pathway. Curr. Opin. Cell Biol. 41 (2016), 100–108.
145. 145 Praissman, J.L., Wells, L., Mammalian O-mannosylation pathway: glycan structures, enzymes, and protein substrates. Biochemistry 53 (2014), 3066–3078.
146. 146 Ohtsubo, K., Marth, J.D., Glycosylation in cellular mechanisms of health and disease. Cell 126 (2006), 855–867.
147. 147 Zhao, Y-Y., et al. Functional roles of N-glycans in cell signaling and cell adhesion in cancer. Cancer Sci. 99 (2008), 1304–1310.
148. 148 Rabinovich, G.A., Toscano, M.A., Turning ‘sweet’ on immunity: galectin–glycan interactions in immune tolerance and inflammation. Nat. Rev. Immunol. 9 (2009), 338–352.
149. 149 Blidner, A.G., et al. Re-wiring regulatory cell networks in immunity by galectin–glycan interactions. FEBS Lett. 589 (2015), 3407–3418.